Business Context and Reporting Period
Company: Revelation Biosciences, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 18, 2026
Event: Special Meeting of Stockholders held to approve the issuance of shares in connection with Class J Common Stock Warrants issued on January 26, 2026.
Key Financial Metrics
This filing is a current report regarding corporate governance and equity structure. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data.
Material Changes
- Warrant Expiration: Following stockholder approval, the expiration date of the Class J Common Stock Warrants is set to March 18, 2031 (five years from the approval date).
- Exchange Cap Approval: Stockholders authorized the issuance of shares that may exceed the 20% Nasdaq "Exchange Cap" limit, satisfying requirements for the Class J Warrants.
- Shareholder Participation: As of the record date, 10,492,469 shares were outstanding. A quorum was established with 4,171,735 shares present or represented by proxy.
Guidance, Outlook, and Risks
Management Commentary: The filing confirms the successful completion of the Special Meeting required to validate the warrant issuance under Nasdaq rules. No forward-looking financial guidance or operational outlook is provided in this document.
Risks and Contingencies: The primary contingency addressed was the potential violation of the Nasdaq Exchange Cap rule without stockholder approval. This risk has been mitigated by the affirmative vote of shareholders.
Investor Verification Checklist
- Verify the total number of shares outstanding (10,492,469) as of the record date for the Special Meeting.
- Confirm the specific terms of the Class J Common Stock Warrants issued on January 26, 2026, including the exercise price and dilution impact.
- Review the definitive proxy statement filed on February 17, 2026, for detailed rationale regarding the warrant inducement.
- Monitor future filings for the actual exercise of warrants and the resulting share count changes.